LAG3 and melanoma: The use of mAbs to target the immunoregulatory checkpoint proteins programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte–associated protein-4 (CTLA-4), or lymphocyte-activation gene-3 (LAG-3) have transformed the management of advanced melanoma (1–3).